Upper Urinary Tract Carcinoma
~Introduction
Upper urinary tract carcinoma (UUTC), also referred to as upper tract urothelial carcinoma (UTUC), is a relatively rare malignancy arising from the urothelial lining of the renal pelvis and ureter. Although urothelial carcinoma most commonly involves the bladder, approximately 5–10% of urothelial cancers occur in the upper urinary tract. Despite its lower incidence, UTUC is clinically significant due to its aggressive nature, diagnostic challenges, and high recurrence risk, particularly in the bladder.
Upper urinary tract carcinoma shares histological features with bladder urothelial carcinoma but differs in epidemiology, molecular profile, and clinical behavior, necessitating distinct diagnostic and therapeutic approaches.
~Epidemiology
UTUC is an uncommon malignancy with an annual incidence of approximately 1–2 cases per 100,000 population. It typically affects individuals between 60 and 75 years of age and shows a male predominance (male-to-female ratio of about 2:1).
Geographical variation is notable. In parts of Asia and the Balkans, UTUC incidence is higher due to exposure to aristolochic acid, a nephrotoxic and carcinogenic compound found in some herbal medicines and plants.
~Etiology and Risk Factors
1. Tobacco Smoking
Smoking is the most important risk factor and is implicated in nearly 50% of UTUC cases. Carcinogens in tobacco smoke are filtered by the kidneys and concentrate in urine, leading to prolonged urothelial exposure.
2. Aristolochic Acid Exposure
Exposure to aristolochic acid (AA), commonly found in certain traditional herbal remedies, is strongly associated with UTUC and causes characteristic DNA adducts and TP53 mutations.
3. Occupational Exposure
Industrial chemicals such as aromatic amines and polycyclic hydrocarbons increase the risk, similar to bladder cancer.
4. Chronic Inflammation
Recurrent urinary tract infections
Urolithiasis
Long-standing obstruction
contribute to urothelial injury and malignant transformation.
5. Genetic Factors
Lynch syndrome (hereditary nonpolyposis colorectal cancer) significantly increases UTUC risk.
Germline mutations in mismatch repair genes (MLH1, MSH2) are commonly implicated.
~Pathogenesis and Molecular Biology
Upper urinary tract carcinoma arises from malignant transformation of urothelial cells. Two major molecular pathways are recognized:
1. Low-Grade Papillary Pathway
Associated with FGFR3 mutations
Characterized by superficial, papillary tumors
High recurrence but relatively favorable prognosis
2. High-Grade Invasive Pathway
Associated with TP53, RB1, and chromatin remodeling gene mutations
Leads to flat carcinoma in situ and invasive disease
Poor prognosis
Compared to bladder cancer, UTUC more commonly presents as high-grade and invasive disease at diagnosis.
~Anatomical Distribution
UTUC may involve:
Renal pelvis (≈70%)
Ureter (≈25%)
Both sites synchronously (≈5%)
Multifocality is common due to the “field cancerization” effect of urothelial carcinogenesis.
~Gross Pathology
Grossly, UTUC appears as:
Papillary, friable masses projecting into the lumen
Flat, ulcerated lesions in carcinoma in situ
Infiltrative thickening of the ureteric wall in advanced disease
Tumors may cause hydronephrosis due to obstruction.
~Histopathology
Microscopic Features
Disordered urothelial architecture
Nuclear pleomorphism
Increased mitotic figures
Loss of cell polarity
Grading
According to WHO classification:
Low-grade urothelial carcinoma
High-grade urothelial carcinoma
Variants
Histological variants include:
Micropapillary
Sarcomatoid
Plasmacytoid
Squamous or glandular differentiation
These variants are associated with aggressive behavior and poorer outcomes.
~Clinical Presentation
The most common presenting symptom is:
Painless gross hematuria
Other clinical features include:
Flank pain due to obstruction
Recurrent urinary tract infections
Dysuria (less common than bladder cancer)
Advanced disease may present with:
Weight loss
Fatigue
Bone pain (metastasis)
~Diagnosis
1. Urinalysis and Urine Cytology
Detection of hematuria
Cytology is particularly sensitive for high-grade tumors
2. Imaging
CT urography (investigation of choice)
MRI urography in patients with renal impairment
Ultrasound for hydronephrosis
3. Ureteroscopy and Biopsy
Direct visualization
Allows tumor biopsy and grading
4. Retrograde Pyelography
Useful when CT urography is contraindicated
~Staging
UTUC is staged according to the TNM system, similar to bladder cancer:
T: Depth of invasion
N: Regional lymph nodes
M: Distant metastasis
Pathological staging after surgery remains the most accurate.
~Treatment
1. Localized Disease
Radical Nephroureterectomy
Gold standard treatment
Removal of kidney, ureter, and bladder cuff
Kidney-Sparing Surgery
Indicated in selected patients:
Low-grade, low-volume tumors
Solitary kidney
Bilateral disease
Includes endoscopic ablation and segmental ureterectomy.
2. Adjuvant and Neoadjuvant Therapy
Cisplatin-based chemotherapy
Intracavitary instillation of BCG or mitomycin in selected cases
3. Advanced and Metastatic Disease
Systemic chemotherapy
Immune checkpoint inhibitors (PD-1/PD-L1)
Targeted therapy (FGFR inhibitors)
~Prognosis
Prognosis depends on:
Tumor stage and grade
Lymph node involvement
Histological variants
Five-year survival rates:
Non-invasive disease: >80%
Muscle-invasive disease: 30–50%
Metastatic disease: <10%
Bladder recurrence occurs in up to 30–50% of patients, requiring long-term surveillance.
~Follow-Up and Surveillance
Long-term follow-up includes:
Periodic cystoscopy
Imaging of the contralateral upper tract
Urine cytology
Surveillance is essential due to high recurrence rates.
~Prevention
Preventive measures include:
Smoking cessation
Avoidance of aristolochic acid–containing herbal products
Occupational safety practices
Genetic counseling for Lynch syndrome patients
~Conclusion
Upper urinary tract carcinoma is a rare but aggressive urothelial malignancy with distinct clinical and biological features compared to bladder cancer. Early diagnosis remains challenging, and many patients present with advanced disease. Advances in imaging, endoscopic techniques, and systemic therapies have improved outcomes, but radical surgery remains the cornerstone of treatment. Lifelong surveillance is essential due to the risk of recurrence and multifocal urothelial involvement.
No comments:
Post a Comment